Cosmos Health Share Buyback Expands to 4.49 Million Shares; Continues Open Market Repurchases

2026-07-14 14:40:00

CHICAGO, July 14, 2026 (GLOBE NEWSWIRE) -- Cosmos Health Inc. ("Cosmos Health" or the “Company”) (NASDAQ:COSM) , a diversified, vertically integrated global healthcare group, today announced that it has repurchased an additional 133,000 shares of its common stock in the open market at an average price of approximately $0.298 per share. The Company has now repurchased a total of approximately 4,488,000 shares for approximately $941,000 under its previously announced share repurchase program of up to $5 million.

Cosmos Health Share Buyback Reaches 4.36 Million Shares; Continues Open Market Repurchases

2026-07-13 15:00:00

CHICAGO, July 13, 2026 (GLOBE NEWSWIRE) -- Cosmos Health Inc. ("Cosmos Health" or the “Company”) (NASDAQ:COSM) , a diversified, vertically integrated global healthcare group, today announced that it has repurchased an additional 215,000 shares of its common stock in the open market at an average price of approximately $0.325 per share. The Company has now repurchased a total of 4,355,000 shares for approximately $901,000 under its previously announced share repurchase program of up to $5 million.

Cosmos Health Accelerates Prescription Medicine Strategy with Libytec Partnership to Commercialize DIABIT-IS X in Greece

2026-07-13 13:00:00

Cosmos Health will supply DIABIT-IS X (sitagliptin), while Libytec handles distribution and promotion in Greece Five-year agreement expected to contribute to revenue and cash-flow visibility As a prescription medicine, DIABIT-IS X is expected to be accessible to patients through Greece's national health insurance system, broadening its potential reach DIABIT-IS X is a generic alternative to Merck's Januvia®, which with Janumet® generated approximately $4.5 billion in combined global sales in 2022 Positions Cosmos Health in the large and established European sitagliptin market CHICAGO, July 13, 2026 (GLOBE NEWSWIRE) -- Cosmos Health Inc. ("Cosmos Health" or the “Company”) (NASDAQ:COSM) , a diversified, vertically integrated global healthcare group, today announced that it has entered into an agreement for the commercialization of its type-2 diabetes medication DIABIT-IS X (sitagliptin phosphate) in the Greek market, through a distribution and promotion partnership with Libytec Pharmaceutical S.A. ("Libytec").

Cosmos Health Accelerates Prescription Medicine Strategy with Libytec Partnership to Commercialize DIABIT-IS X in Greece

2026-07-13 13:00:00

Cosmos Health will supply DIABIT-IS X (sitagliptin), while Libytec handles distribution and promotion in Greece Five-year agreement expected to contribute to revenue and cash-flow visibility As a prescription medicine, DIABIT-IS X is expected to be accessible to patients through Greece's national health insurance system, broadening its potential reach DIABIT-IS X is a generic alternative to Merck's Januvia, which with Janumet generated approximately $4.

Cosmos Health Launches Subscription Model

2026-07-10 10:55:00

Subscription model already launched with NOOR Collagen in the United States Early data shows a repeat purchase rate above 60% at high margins in excess of 50% Model is designed to drive stronger loyalty, greater lifetime value, and more predictable cash-flow visibility Company plans to extend the subscription model to additional Cosmos Health products globally, with further initiatives already underway CHICAGO, July 10, 2026 (GLOBE NEWSWIRE) -- Cosmos Health Inc. ("Cosmos Health" or the “Company”) (NASDAQ:COSM) , a diversified, vertically integrated global healthcare group, today announced that it has launched a subscription-based purchasing model for its proprietary consumer health brands. The model is currently live with NOOR Collagen in the United States, with encouraging early results that include a repeat purchase rate above 60% and margins in excess of 50%.

Cosmos Health Launches Subscription Model

2026-07-10 10:55:00

Subscription model already launched with NOOR Collagen in the United States Early data shows a repeat purchase rate above 60% at high margins in excess of 50% Model is designed to drive stronger loyalty, greater lifetime value, and more predictable cash-flow visibility Company plans to extend the subscription model to additional Cosmos Health products globally, with further initiatives already underway CHICAGO, July 10, 2026 (GLOBE NEWSWIRE) -- Cosmos Health Inc.

Cosmos Health Expands Share Buyback to 4.14 Million Shares; Continues Open Market Repurchases

2026-07-09 15:45:00

CHICAGO, July 09, 2026 (GLOBE NEWSWIRE) -- Cosmos Health Inc. ("Cosmos Health" or the “Company”) (NASDAQ:COSM) , a diversified, vertically integrated global healthcare group, today announced that it has repurchased an additional 80,000 shares of its common stock in the open market at an average price of approximately $0.2503 per share. The Company has now repurchased a total of 4,140,000 shares for approximately $831,000 under its previously announced share repurchase program of up to $5 million.

Cosmos Health Share Buyback Surpasses 4 Million Shares; Continues Open Market Repurchases

2026-07-08 15:40:00

CHICAGO, July 08, 2026 (GLOBE NEWSWIRE) -- Cosmos Health Inc. (“Cosmos Health” or the “Company”) (NASDAQ:COSM) , a diversified, vertically integrated global healthcare group, today announced that it has repurchased an additional 190,000 shares of its common stock in the open market at an average price of approximately $0.2805 per share. The Company has now repurchased a total of 4,060,000 shares for approximately $811,000 under its previously announced share repurchase program of up to $5 million.